Literature DB >> 15030792

The niemann-pick disease genes; regulators of cellular cholesterol homeostasis.

Daniel S Ory1.   

Abstract

Cellular cholesterol homeostasis is maintained through activation of the designated sterol regulatory element binding proteins and liver X receptor transcriptional pathways. Insight into the molecular mechanisms that regulate these pathways has come from the study of Niemann-Pick C (NPC) disease. Mutations in the NPC1 and NPC2 disease genes lead to lysosomal accumulation of cholesterol and defects in regulation of sterol homeostatic responses. NPC1 and NPC2 are key participants in intracellular cholesterol trafficking and are required for production of low-density lipoprotein cholesterol-derived oxysterols. In this review, the function of NPC1 and NPC2 in sterol trafficking and regulation of cholesterol homeostasis is examined. Study of the NPC proteins will further understanding of the mechanisms involved in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030792     DOI: 10.1016/j.tcm.2003.12.003

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  37 in total

Review 1.  Niemann-pick disease type C: implications for sedation and anesthesia for diagnostic procedures.

Authors:  Ning Miao; Xiaowei Lu; Naomi P O'Grady; Nicole Yanjanin; Forbes D Porter; Zenaide M N Quezado
Journal:  J Child Neurol       Date:  2012-02-28       Impact factor: 1.987

2.  Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis.

Authors:  Navin Rauniyar; Kanagaraj Subramanian; Mathieu Lavallée-Adam; Salvador Martínez-Bartolomé; William E Balch; John R Yates
Journal:  Mol Cell Proteomics       Date:  2015-04-14       Impact factor: 5.911

3.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

Review 4.  Regulation of cholesterol homeostasis.

Authors:  Leigh Goedeke; Carlos Fernández-Hernando
Journal:  Cell Mol Life Sci       Date:  2011-10-19       Impact factor: 9.261

5.  Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C.

Authors:  Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

Review 6.  Macrophage-related diseases of the gut: a pathologist's perspective.

Authors:  Xavier Sagaert; Thomas Tousseyn; Gert De Hertogh; Karel Geboes
Journal:  Virchows Arch       Date:  2012-05-11       Impact factor: 4.064

7.  Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.

Authors:  Niklas Mattsson; Henrik Zetterberg; Simona Bianconi; Nicole M Yanjanin; Rao Fu; Jan-Eric Månsson; Forbes D Porter; Kaj Blennow
Journal:  JIMD Rep       Date:  2011-09-28

8.  δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.

Authors:  Miao Xu; Ke Liu; Manju Swaroop; Forbes D Porter; Rohini Sidhu; Sally Firnkes; Sally Finkes; Daniel S Ory; Juan J Marugan; Jingbo Xiao; Noel Southall; William J Pavan; Cristin Davidson; Steven U Walkley; Alan T Remaley; Ulrich Baxa; Wei Sun; John C McKew; Christopher P Austin; Wei Zheng
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 9.  Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking.

Authors:  Judith Storch; Zhi Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-13

Review 10.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.